Your browser doesn't support javascript.
loading
Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells.
Brennan, Patrick J; Saunders, Rebecca E; Spanou, Mary; Serafini, Marta; Sun, Liang; Heger, Guillaume P; Konopacka, Agnieszka; Beveridge, Ryan D; Gordon, Laurie; Bunally, Shenaz B; Saudemont, Aurore; Benowitz, Andrew B; Martinez-Fleites, Carlos; Queisser, Markus A; An, Heeseon; Deane, Charlotte M; Hann, Michael M; Brayshaw, Lewis L; Conway, Stuart J.
Afiliação
  • Brennan PJ; Department of Chemistry, Chemistry Research Laboratory, University of Oxford; Oxford, UK.
  • Saunders RE; Department of Chemistry & Biochemistry, University of California, Los Angeles; Los Angeles, USA.
  • Spanou M; GSK, Medicines Research Centre; Stevenage, UK.
  • Serafini M; PerkinElmer; Beaconsfield, UK.
  • Sun L; Department of Chemistry, Chemistry Research Laboratory, University of Oxford; Oxford, UK.
  • Heger GP; Chemical Biology Program, Memorial Sloan Kettering Cancer Center; New York, USA.
  • Konopacka A; GSK, Medicines Research Centre; Stevenage, UK.
  • Beveridge RD; GSK, Medicines Research Centre; Stevenage, UK.
  • Gordon L; Virus Screening Facility, Weatherall Institute of Molecular Medicine, University of Oxford; Oxford, UK.
  • Bunally SB; GSK, Medicines Research Centre; Stevenage, UK.
  • Saudemont A; GSK, Medicines Research Centre; Stevenage, UK.
  • Benowitz AB; GSK, Medicines Research Centre; Stevenage, UK.
  • Martinez-Fleites C; GSK, Medicines Research Centre; Stevenage, UK.
  • Queisser MA; GSK, Medicines Research Centre; Stevenage, UK.
  • An H; GSK, Medicines Research Centre; Stevenage, UK.
  • Deane CM; Chemical Biology Program, Memorial Sloan Kettering Cancer Center; New York, USA.
  • Hann MM; Department of Statistics, University of Oxford; Oxford, UK.
  • Brayshaw LL; GSK, Medicines Research Centre; Stevenage, UK.
  • Conway SJ; GSK, Medicines Research Centre; Stevenage, UK.
bioRxiv ; 2024 Mar 16.
Article em En | MEDLINE | ID: mdl-38559242
ABSTRACT
Immunomodulatory imide drugs (IMiDs) including thalidomide, lenalidomide, and pomalidomide, can be used to induce degradation of a protein of interest that is fused to a short zinc finger (ZF) degron motif. These IMiDs, however, also induce degradation of endogenous neosubstrates, including IKZF1 and IKZF3. To improve degradation selectivity, we took a bump-and-hole approach to design and screen bumped IMiD analogs against 8380 ZF mutants. This yielded a bumped IMiD analog that induces efficient degradation of a mutant ZF degron, while not affecting other cellular proteins, including IKZF1 and IKZF3. In proof-of-concept studies, this system was applied to induce efficient degradation of TRIM28, a disease-relevant protein with no known small molecule binders. We anticipate that this system will make a valuable addition to the current arsenal of degron systems for use in target validation.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article